Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response

American Journal of Hematology

Volumn 77, Issue 4, 2004, Pages 329-330

  Ghobrial, Irene M ^a   Uslan, Daniel Z ^a   Call, Timothy G ^a   Witzig, Thomas E ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cryoglobulin; Rituximab; Ulceration; Waldenstr m

Indexed keywords

CRYOGLOBULIN; RITUXIMAB;

AGED; ARTICLE; CASE REPORT; CRYOGLOBULINEMIA; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE COMPLEX DEPOSITION; PRIORITY JOURNAL; SKIN NECROSIS; SKIN ULCER; TREATMENT FAILURE; VASCULITIS; WALDENSTROEM MACROGLOBULINEMIA;

AGED; ANTIBODIES, MONOCLONAL; CRYOGLOBULINEMIA; CRYOGLOBULINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULATION TISSUE; HUMANS; INJECTIONS, INTRAVENOUS; LEG ULCER; TREATMENT OUTCOME; VASCULITIS; WALDENSTROM MACROGLOBULINEMIA;

EID: 9644270590     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20207     Document Type: Article

References (8)

1. Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999;13:1315-1349.
2. Tavoni A, Mosca M, Ferri C, et al. Guidelines for the management of essential mixed cryoglobulinemia. [review] Clin Exp Rheumatol 1995;13(Suppl 13):S191-S195.
3. Pechere-Bertschi A, Schifferli JA. Essential cryoglobulinemia. Schweiz Rundsch Med Prax 1993;82(6):163-167 [article in French].
4. Geltner D, Kohn RW, Gorevic P, Franklin EC. The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement. Arthritis Rheum 1981;24(9):1121-1127.
5. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827-3834 [Epub 2003 Jan 30].
6. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101(10):3818-3826 [Epub 2002 Dec 27].
7. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia [letter]. Haematologica 1999;84:1157-1158.
8. Zaja F, De Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinemia [letter]. Arthritis Rheum 2002;46:2252-2254.